|
Download
PDF
|
Commercial Insight:
Antibacterials - Growth in resistance rates drives niche
indications
The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizer's Zithromax) in 2005.
View
Table Of Contents >
|
